No. 46Articles
On this page

All reading for this session

· No. 046

Market analysis

STIM Gapped 22.57%. Greenbrook Supplied About 94% of the Revenue Increase.

Illustration of stacked translucent sheets, with the front sheet highlighted.
Illustration of stacked translucent sheets, with the front sheet highlighted.

Public sources checked through November 11, 2026, at 5:28 p.m. ET.

Neuronetics opened at $2.77 on Nov. 4, up 22.57%, and closed at $2.71. Its premarket release showed quarterly revenue up 12.5% to about $42 million, with adjusted EBITDA swinging from a $4.67 million loss to a $1.89 million profit. Greenbrook supplied almost all the additional revenue. Both divisions contributed to the improvement in segment profit. Nov. 4 FennEdge recap · Premarket filing and acceptance time · Quarterly 10-Q

The clinics added $4.38 million in revenue

In the quarter ended Sept. 30, Greenbrook clinic revenue increased from $21.81 million to $26.19 million, a gain of about $4.38 million. That accounted for about 94% of the company’s $4.67 million increase. NeuroStar added about $280,000. The filing recast the year-earlier numbers under the current segment structure, so the two periods use the same reporting basis. 10-Q segment revenue tables

Both divisions helped the profit line

Greenbrook’s quarterly segment result swung from a loss of about $970,000 to a profit of $3.11 million. NeuroStar’s segment profit went from roughly $290,000 to $4.81 million, helped by a drop in direct selling and administrative expenses from $9.14 million to $6.22 million. After unallocated corporate expenses, Neuronetics reported about $540,000 of operating income, compared with a $7.32 million operating loss a year earlier. 10-Q segment expenses and consolidated operating income

The company still recorded a consolidated net loss of about $1.56 million that quarter. The Nov. 4 filing said Neuronetics complied with its loan covenants at Sept. 30, 2026, but projected that trailing twelve-month revenue could fall below the required threshold for March 31, 2027. It disclosed substantial doubt about its ability to continue as a going concern. The lender’s test is tied to the credit agreement’s revenue requirement and the company’s ability to repay. 10-Q liquidity and credit covenants

This article explains common concepts; examples are not trading recommendations.